Expanding the Druggable Landscape: Targeting Signalling, Cytoskeletal & Chromatin Pathways to Unlock Next-Generation RAS Combination Strategies

• Identifying novel druggable vulnerabilities across signalling, cytoskeletal, and chromatin networks to open new therapeutic opportunities beyond conventional targets
• Targeting protein-protein interactions and defining optimal developmental treatment windows to maximize inhibitor impact while improving translational success
• Leveraging RAC and RAS pathway biology alongside a predictive combination platform to design rational therapies, validated through pioneering brain cancer research and published studies

Speakers:

Nagi Ayad

Professor

Georgetown University